Published in Hepatitis Weekly, August 20th, 2001
To study how patients on dialysis respond to IFN/ribavirin dosing regimens normally given to HCV patients not on dialysis, researchers at the Karolinska Institute and Huddinge University Hospital in Stockholm, Sweden, enrolled five hemodialysis patients and one peritoneal dialysis patient, all infected with HCV, in a 28-week trial of the combination therapy.
Overall, four patients were able to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.